Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer

Leal, Alessandro; Mathios, Dimitrios; Jakubowski, Debbie; Johansen, J.; Lau, Anna; Wu, Tony; Cristiano, Stephen; Medina, Jamie E.; Phallen, Jillian; Bruhm, Daniel C.; Carey, Jacob; Dracopoli, Nicholas C.; Bojesen, Stig E.; Scharpf, Robert B.; Velculescu, Victor E.; Vachani, Anil

doi:10.1016/j.chest.2023.04.033

Cited by 6 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fragmentomics is an emerging field of study focused on analyzing fragments of DNA, RNA, and other molecules shed by cells into bodily fluids like blood ( Medina et al, 2023 ). This approach is gaining traction in oncology due to its’ potential to provide insights into the molecular characteristics of diseases, including cancer, without the need for invasive biopsies ( Mathios et al, 2021 ; Leal et al, 2023 ).…”

Section: Next-generation Sequencing: a New Standard In Cancer Managementmentioning

confidence: 99%

Next-generation sequencing impact on cancer care: applications, challenges, and future directions

Zalis,

Viana Veloso,

Aguiar Jr.

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

Fundamentally precision oncology illustrates the path in which molecular profiling of tumors can illuminate their biological behavior, diversity, and likely outcomes by identifying distinct genetic mutations, protein levels, and other biomarkers that underpin cancer progression. Next-generation sequencing became an indispensable diagnostic tool for diagnosis and treatment guidance in current clinical practice. Nowadays, tissue analysis benefits from further support through methods like comprehensive genomic profiling and liquid biopsies. However, precision medicine in the field of oncology presents specific hurdles, such as the cost-benefit balance and widespread accessibility, particularly in countries with low- and middle-income. A key issue is how to effectively extend next-generation sequencing to all cancer patients, thus empowering treatment decision-making. Concerns also extend to the quality and preservation of tissue samples, as well as the evaluation of health technologies. Moreover, as technology advances, novel next-generation sequencing assessments are being developed, including the study of Fragmentomics. Therefore, our objective was to delineate the primary uses of next-generation sequencing, discussing its’ applications, limitations, and prospective paths forward in Oncology.

show abstract

Section: Next-generation Sequencing: a New Standard In Cancer Managementmentioning

confidence: 99%

Next-generation sequencing impact on cancer care: applications, challenges, and future directions

Zalis,

Viana Veloso,

Aguiar Jr.

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

COUNTERPOINT: Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Not Yet!

Nadig,

Smyth,

Bade

2024

CHEST Pulmonary

View full text Add to dashboard Cite

Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial

Boeri,

Sabia,

Ledda

et al. 2024

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer

Cited by 6 publications

References 41 publications

Next-generation sequencing impact on cancer care: applications, challenges, and future directions

Next-generation sequencing impact on cancer care: applications, challenges, and future directions

COUNTERPOINT: Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Not Yet!

Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial

Contact Info

Product

Resources

About